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Background: In Ecuador, cutaneous leishmaniasis (CL) is prevalent countrywide, but only one case of diffuse-CL
and two cases of disseminated-CL were experienced during our research activities more than 30 years from 1982
to date. These three patients suffered from multiple lesions distributed at a wide range of the body surface,
revealing difficulty to clinically differentiate each other.
Methods: There is a considerable confusion of the use and/or differentiation of the terminologies (terms)
between the two disease forms, diffuse-CL and disseminated-CL. One of the aims of the present study is to
clarify the difference between the two disease forms, mainly based on the cases experienced in Ecuador.
Results: The disseminated-CL case newly reported here was clinically very similar to the diffuse-CL case, but the
former showed the following marked differences from the latter: (1) the organisms isolated were identified as
the parasites of Leishmania (Viannia) guyanensis/panamensis, which are also known as the causative agents of
disseminated-CL in different endemic countries of the New World; (2) the patient was sensitive against antimonials;
and (3) mucosal involvement was observed, which is never observed in diffuse-CL.
Conclusions: In the text, three clinical cases, one diffuse-CL and two disseminated-CL, were presented. Furthermore,
a bibliographic comparison of the features between the two disease forms was made, and a brief comment was
also given.
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Leishmaniases are one of the vector-borne diseases,
caused by obligate intra-macrophage protozoan parasites
of the genus Leishmania, with subgenera Leishmania and
Viannia. The disease is transmitted by the bite of infected
female phlebotomine sand flies of the genera Phlebotomus
and Lutzomyia in the Old and New Worlds, respectively.
In humans, about 20 Leishmania species are responsible
for a wide spectrum of clinical manifestations, ranging
from localized cutaneous leishmaniasis (CL) to those pro-
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different types of the disease are endemic in many tropical
and subtropical regions and responsible for increasing
health problems in large parts of the world [1, 2].
The diffuse-CL case was reported for the first time by
Convit and Lapenta from Venezuela in the New World
and then by Destombes et al. from Ethiopia in the Old
World [3, 4]. The former authors reported one case as an
atypical clinical form in Spanish version entitled “Sobre un
caso de leishmaniasis tegmentaria de forma diseminada”
(one case of disseminated form of tegumentary leishman-
iasis) in a Venezuelan medical journal. Later, the latter au-
thors reported a similar case from Ethiopia in French
version entitled “Leishmaniose cutanee nodulaire dissemi-
nee en Ethiopie” (disseminated cutaneous nodular leish-
maniasis in Ethiopia). The authors of the two articles usedticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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forms in the title. After these reports, some workers
like to use “disseminate” against diffuse-CL and
others used “diffuse” against the same disease form
(diffuse-CL). On the other hand, disseminated-CL
cases in the New World were reported for the first
time by Costa et al. and then by Carvalho et al. and
Turetz et al. from Brazil [5–7]. The disseminated-CL
is mainly found in the New World.
Thus, for many years, diffuse-CL and disseminated-CL
remain clinical forms of the well-classified skin mani-
festations of the disease. Still, however, there is a con-
siderable confusion of the utilization or differentiation
of the terminology between the two disease forms. We
therefore tried to emphasize the correct and precise
differentiation of the two clinical forms. In the text, three
clinical cases, one diffuse-CL and two disseminated-CL,
were presented. Furthermore, a brief review was given,
performing a bibliographic comparison between the two
disease forms. Informed consent was obtained from the
subjects who participated.Fig. 1 Map of Ecuador, showing the localities from which patients with diffus
province: one case of diffuse-CL; 2 Balao Chico, Guayas province: one cas
disseminated-CLMethods
Patient’s origin and identification of Leishmania species
Patients’ localities
We experienced one case of diffuse-CL from Muisne,
Esmeraldas province, and two cases of disseminated-CL
from Balao Chico, Guayas province, and more recently
from Cumanda, Chimborazo province, respectively (Fig. 1).
Clinical samples from patients
Clinical samples from diffuse-CL (Muisne) and dissemi-
nated-CL (Cumanda) were taken by scraping the margin
of active lesions of the patients, spotted onto a FTA classic
card (Whatman, Newton Center, MA), and stored at room
temperature. Disks 2 mm in diameter were punched
out from each filter paper and washed three times
with FTA purification reagent (Whatman) and once
with Tris-EDTA buffer. The disks were air-dried and
directly subjected to PCR amplification. Nested PCR
was performed to amplify the Leishmania cytochrome
b (cyt b) gene from a patient specimen collected on
the FTA cards. Primers used for the nested PCR weree-CL and disseminated-CL cases were reported. 1 Muisne, Esmeraldas
e of disseminated-CL; 3 Cumanda, Chimborazo province: one case of
Fig. 2 a, b Diffuse-CL case: a Rice-grain to thumb-sized reddish
nodules and papules were observed on the ear lobes, auricles, face,
and shoulders. b Various types of eruptions, such as papules, nodules,
infiltrated erythemas, and brownish-colored freckles, were found on
the lower extremities. Induration of the lesions was palpable. c, d
Disseminated-CL case: c Superficial involvement of mucosae was
recognized on the nose and lip, with partial ulceration. d Multiple
and confluent lesions were observed on a wide range of the lower
extremities with partial ulceration
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L.cyt-AR (5′-CCACTCATAAATA TACTATA-3′) for the
first PCR and L.cyt-S and L.cyt-R for the second PCR [8, 9].
Montenegro (Leishmanin) skin test and recombinant
kinesin-like antigen (rK39) kit test
To see the cellular immune response of the subjects exam-
ined, intradermal skin test antigen derived from Leishmania
(Viannia) panamensis promastigotes was applied to the
subjects; more than 5 mm in diameter of the induration
was considered as positive [10]. Besides, recombinant
kinesin-like K39 kit test (rK39 antigen of L. (Leishmania)
chagasi produced by InBios International (Kalazar Detect™
Rapid Test kit, Seattle, WA, USA )) was applied to the sera
of the subjects, in order to see humoral immune response.
Phylogenetic analysis
Cytochrome b (cyt b) gene sequence was performed with
CLUSTAL W software [11] and examined using the pro-
gram MEGA (Molecular Evolutionary Genetics Analysis)
version 5.1 [12]. Phylogenetic trees were constructed by
the neighbor-joining method with the distance algorithms
available in the MEGA package. Bootstrap values were
determined with 1000 replicates of the data sets. The
database for phylogenetic analyses consisted of cyt b gene
sequences from GenBanks of 12 Leishmania species.
Results
Diffuse and disseminated cutaneous leishmaniasis in
Ecuador
A case of diffuse cutaneous leishmaniasis (diffuse-CL)
We experienced a case of diffuse-CL [13]. The patient
was a 24-year-old male (Fig. 2a, b) and was born and
grew up in a small village near the Pacific coast of
Ecuador, San Ignacio, Muisne, Esmeraldas province, a
rural and mountainous area, located at 20 m above sea
level (a.s.l.) (Fig. 1 (1)). In our epidemiological survey in
the area, none of the patient’s family members and neigh-
boring people revealed diffuse-CL cases (Hashiguchi et al.,
unpublished data). When the patient was 16 years old,
papules appeared on his left knee and right cheek. The
eruption gradually increased in size and number. For
about 2 years, he received various medications without
confirmed diagnosis. Then, he was diagnosed clinically
with leprosy and received the specific medication (mul-
tidrug treatment: dapsone, rifampicin, and clofazimine)
for 1 month. After precise clinical and laboratory exam-
inations, he was finally diagnosed with a diffuse-CL at
the Department of Parasitology, National Institute of
Tropical Medicine and Hygiene, Guayaquil city, Ecuador,
with positive smears for Leishmania parasites. Montenegro
(Leishmanin) skin test was negative, but tuberculin,
candidine, and trichophytin skin tests revealed positive
reactions, demonstrating the existence of specificanergy against Leishmania antigen. On the other hand,
the rK39 kit test revealed a strong positive reaction,
suggesting the high-level function of humoral immune
system of the diffuse-CL patient.
Physical examinations revealed pea- to rice-grain-sized
reddish papules on both the ear lobes and the auricles.
Induration of the lesions was palpable. Miliary to pea-
sized reddish papules were observed on the face. The
papules and nodules were also observed on the left
shoulder. Many miliary to hen-egg-sized papule, nodule,
erythema, infiltrated erythema, and brownish-colored
freckles were observed on the upper extremities. The
surfaces of some of the nodules were scaly and crusted.
Rice-grain to thumb-sized reddish papules grouped on
the brownish-colored freckle lesion on the lower back
were observed. Miliary-sized papules were scattered
showing satellite lesions around the plaque-like lesions.
Thumb- to palm-sized erythema was observed on the
thigh. No loss of sensation was recognized. Various types
of eruptions, such as papules, nodules, infiltrated ery-
thema, and brownish-colored freckles, were observed on
the lower extremities. There were no eruptions on the
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guinal, perineal, and anal regions, except a few verruca
vulgaris lesions on the dorsal aspect of the left hand.
There was no sensory loss on all over the body surface
and no hypertrophy of the peripheral nerve. Numerous
Leishmania amastigotes were observed in the stained
smears from the skin lesion, though no acid-fast bacilli
were observed in the slit-skin smear materials with
Ziehl-Neelsen staining. The parasite was identified as L.
(L.) mexicana by PCR analysis (Fig. 3).
Histological findings of the specimen taken from nod-
ules on the thigh showed hyperkeratosis and mild
acanthosis of the dermis. There was dense cellular infil-
tration in the dermis. Proliferations of blood vessels were
also visible. In the foamy cells, innumerable Leishmania
amastigotes were observed. No epithelioid cell granu-
loma was observed as seen in leprosy. No acid-fast
bacilli were observed in the dermis. The patient was
treated with meglumine antimoniate (Glucantime®) at
a dose of 10 mg/kg/day and sodium stibogluconate
(Pentostam®) at a dose of 20 mg/kg/day for 28 days
with each drug; partial resolution of skin lesion was
observed but relapsed soon after discontinuation of
the treatment. In these treatments, the density of para-
site on smear specimens was significantly reduced
immediately after the beginning of each treatment but
never disappeared completely. Thus, relapses were
followed by 5- or 6-month intervals after each of the
slight clinical improvements. Therefore, the patient
had to receive repeatedly the intramuscular injection
of Glucantime® after each relapse. Following thisFig. 3 Phylogenetic tree of cyt b gene sequences among species. Cyt b ge
patients with diffuse-CL (DCL) and disseminated-CL (DSL). A phylogenetic ana
method together with sequences from 12 Leishmania species. The scale bar r
below branchesantimonial treatment, the patient received also pent-
amidine (3–4 mg/kg intramuscularly once or twice for
a week) but had to be discontinued because of severe
adverse reactions such as hypotension, gastrointestinal
symptoms, and syncope, without revealing a marked
clinical and parasitological healing. Subsequently, the
patient was treated with oral itraconazole (200 mg/day for
3 months), mefloquine (4.2 mg/kg/day for 6 days, repeated
with a 3-week interval), and artesunate (6.7 mg/kg/day for
3 days, repeated with a 2-week interval), but compete
healing was not obtained by any of these drugs. These
mixed and alternative treatments were performed one
after another because of the lack of any effective drugs for
this diffuse-CL patient. The patient was also treated with
oral miltefosine [13, 14]. The drug (Impavido®) was started
at a dose of 2.5 mg/kg/day and continued for 5 months.
However, 2 months after discontinuing miltefosine,
small papular lesions appeared and the slit-skin smears
and aspirates of lesions had become positive for Leish-
mania parasites. Miltefosine was re-started at the same
dose, but no clinical or parasitological response was ob-
served even after 2 months of re-treatment, and skin
lesions continued to grow and spread over the entire
body [14]. No specific and efficient drug is available for
the diffuse-CL in the world at the moment.
Two cases of disseminated cutaneous leishmaniasis
(disseminated-CL)
The first case of disseminated-CL
We diagnosed the first case of disseminated-CL in
Ecuador and named it as “generalized CL” [15]. Thenes of the Leishmania parasites were amplified and sequenced from
lysis of cyt b gene sequences was performed by the neighbor-joining
epresents 0.01 % divergence. Bootstrap values are shown above or
Fig. 4 Disseminated-CL case, before and after the treatment. At the
time of our examination, the patient already received injections of
nine ampoules of trivalent antimonials (Repodral®) at the Cumanda
health center. After finishing several courses of the treatment, he
received another drug, pentavalent antimonials (Glucantime®)
during about 5 months, responding well to the treatment. a, c Before
the treatment, photographed on February 26, 2006. b, d After the
treatment, photographed on August 17, 2006
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ination (August 1979). The patient came from a small
village, Balao Chico, Guayas province, a mountainous
area located at 200 m a.s.l. (Fig. 1 (2)). At the early phase
of the disease, the lesion appeared on the lumbar region,
and then papular lesions were seen, which became pus-
tulous vesicles at the right lumber region and dissemi-
nated all over the body, demonstrating 308 generalized
lesions counted. The patient revealed a marked right
lumbar pain, and some of the lesions in the body surface
suspecting herpes zoster were observed. The patient was
admitted for 16 days in a private hospital and then was
taken to a national hospital “Hospital Luis Vernaza” in
Guayaquil city, Ecuador. She was admitted to the hos-
pital under the suspected diagnosis of smallpox, being
registered No. 03739 in August 1979, without a precise
diagnosis. As there was no improvement of her lesions
on the 15th day of admission, she was taken to receive
differential diagnosis at the National Institute of Tropical
Medicine and Hygiene, Guayaquil city, Ecuador. The
presumptive clinical diagnoses were paracoccidioido-
mycosis, cutaneous leishmaniasis, or staphylococcal
infections. Firstly, the case was considered as paracoc-
cidioidomycosis suggesting a generalized cutaneous
form of the disease. But either Paracoccidioides braziliensis
or Staphylococcus aureus were not observed in the examin-
ation of ulcer materials. Laboratory examinations revealed
positive for betahemolytic streptococcus and sensitive for
erythromycin, cephalexin, amikacin, and ampicillin and
stool examination positive for Trichuris trichiura, Ascaris
lumbricoides, and Ancylostoma duodenale.
Most of the ulcer was crusty. When lifting the crusts,
they were excavated with a purulent fluid because of
sever secondary infections. The ulcers had different sizes
ranging from 0.5 to 20 mm in diameter. Some lesions
had thick, prominent, and adhered crusts that bleed eas-
ily when they were separated. Others were small crusty
ulcers that left an excavation, and some of them were
erythematous and papulous, and confluent plaques
were found on the lumbar-dorsal region. Several smear
samples from diverse regions of the body surface were
taken at random. The samples were positive for the
Leishmania amastigote, though the number was scanty
in smear specimens. The parasite isolated was identified
as L. (V.) panamensis (designated as MHOM/EC/95/
NA-03) by ELISA species-specific monoclonal anti-
bodies (serodeme) analysis [16]. No Montenegro skin
test and rK39 kit test were performed in the case. The pa-
tient responded well to Glucantime® treatment (6.5 mg/
kg/day for 12 days). In this case, both metronidazole per
os and its ointment were also used as a supplementary
treatment; probably, these accelerated the patient’s healing
within a short regimen, in spite of a relatively low dose of
the drug.The second case of disseminated-CL
More recently, we experienced the second case of
disseminated-CL in Ecuador, which was clinically very
similar to diffuse-CL. The patient was a 43-year-old
male, as of February 22, 2006 (Fig. 2c, d), and came from
a small community “Barrio 28 de Enero,” Chimborazo
province, a subtropical mountainous area at the begin-
ning of Andean slopes, located at 500 m a.s.l. (Fig. 1 (3)).
The lesion began with an insect bite-like papular lesion
on the forearm. Then, the lesions appeared on the right
ear and the nose. About 2 years later, lesions appeared
on a wide range of the lower extremities, followed by
multiple and confluent lesions on the abdomen, thorax,
body side, and thigh (photographs not shown). A super-
ficial involvement of mucosae of the nose and upper lip
was observed as seen in Fig. 4a. At the time of examin-
ation in the National Institute of Tropical Medicine and
Hygiene, the patient already received injections of nine
ampoules of trivalent antimonials Repodral® (20 mg/kg/
day) at a rural health center (Cumanda, Guayas prov-
ince). After finishing several courses of the treatment,
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about 5 months and responded well to the treatment.
Montenegro skin test showed positive with a 17-mm
induration, and rK39 kit test revealed a strongly positive
band, suggesting a higher level of functions of the
humoral immune system(s). Smear specimens, skin bi-
opsies, syringe aspirates for in vitro cultures, and mate-
rials on FTA® classic cards (Whatman®) were taken from
the active lesions. The smear specimen revealed positive
for the Leishmania amastigote with a scanty number.
Promastigotes grown in vitro had a tendency to decrease
gradually after several days of cultivation and then totally
disappeared, probably because of the effect of previous
treatment with Repodral® before the material aspiration for
culture. The parasites from the biopsy and FTA® card ma-
terials were identified as L. (V.) guyanensis by PCR analysis
(Fig. 3). Thus, the case was clinically very similar to
diffuse-CL but showed the following marked differences:
(1) the organisms isolated were identified as the subgenus
Viannia, L. (V.) guyanensis, which is also known as one of
the causative agents of disseminated-CL in different
endemic countries of the New World; (2) the patient
was sensitive against antimonials; and (3) the superficial
involvement of mucosae was recognized as seen in Fig. 2c,
such a mucosal sign is never seen in diffuse-CL cases.
The patient was alcoholic, and complications of his liver
cirrhosis led to the unexpected death after healing of
disseminated-CL.
Discussion
In Ecuador, there are 24 provinces; among them, leish-
maniases are prevalent in 21 provinces except Galapagos
Is. As the causative agent of the Leishmania spp., there
are eight species in total, L. (L.) mexicana, L. (L.) amazo-
nensis, L. (L.) major-like, L. (V.) braziliensis, L. (V.) guya-
nensis, L. (V.) panamensis, L. (V.) naiffi [9, 17, 18], and
the newly found L. (V.) lainsoni (Kato et al., unpub-
lished data). In the country, localized CL is the most
frequent clinical feature of the disease, followed by
MCL cases mainly seen in the Ecuadorian Amazonian
region [17, 18]. Only one diffuse-CL and two disseminated-
CL cases in Ecuador were confirmed parasitologically and/
or molecular biologically in our research activities from
1982 to date. No VL case was recorded, and its suspected
vector species, Lutzomyia longipalpis and L. evansi, are not
recorded among 29 species of man-biting sand flies [19].
The present diffuse-CL and disseminated-CL cases are
found in the littoral northern (Esmeraldas) and southern
(Guayas and Chimborazo) Ecuadorian regions. There
will be a possibility of the presence of some unreported
cases, especially in the Ecuadorian Amazonian regions,
where the disease with diverse clinical manifestations are
highly endemic, caused by different Leishmania species
mentioned above.Leishmaniases are caused by the parasites of the genus
Leishmania, in which two subgenera Leishmania and
Viannia exist. In the Old World, only the subgenus
Leishmania is prevailing, while in the New World, both
subgenera Leishmania and Viannia are circulating. The
subgenus Leishmania parasites are causative agents of
diffuse-CL in both the Old and New Worlds. The causa-
tive agents of diffuse-CL in the Old World are L. (L.)
aethiopica and to a lesser extent L. (L.) major [20] and
L. (L.) amazonensis and L. (L.) mexicana in the New
World [21]. In the Old World, the clinical form of
diffuse-CL is uncommon other than east Africa, Ethiopia,
and Kenya [4, 22], but one each of cases masquerading as
leprosy in the context of human immunodeficiency virus
(HIV) co-infection was reported from Burkina Faso [23]
and from Senegal [20]. On the other hand, in the New
World, species of the subgenus Leishmania, such as L. (L.)
mexicana and L. (L.) amazonensis, are responsible for the
diffuse-CL in a wide range of South and Central American
countries [21]. Among them, L. (L.) mexicana is mainly
reported from the Central American countries and from a
part of the northern regions of the South America [24].
No diffuse-CL cases caused by species of the subgenus
Viannia are reported to date. The diffuse-CL lesions grow
and proliferate as nodules and plaques which slowly but
relentlessly spread to cover the entire body, with the
exception of the scalp, axillae, inguinal fold, palms of the
hands, and soles of the feet [25–28]. The diffuse-CL is a
rare disease entity, and no more than 1–2 cases are
diagnosed in all of Brazil each year [29].
The use of the terms, diffuse-CL and disseminated-
CL, are frequently cited with a considerable confusion
in literatures. In Brazil, many disseminated-CL cases
were reported [5, 7, 13, 25, 26, 28]. Among them, a
disseminated-CL case with 425 lesions caused by L. (V.)
guyanensis was diagnosed both clinically and parasito-
logically [30]; in the text, however, the terminology
(term) of both “disseminated” and “diffuse” against
the disseminated-CL case was used without precisely
differentiating the two disease forms, diffuse-CL and
disseminated-CL. Nowadays, clear differences between the
two forms were accumulated in literatures as shown in
Table 1 [7, 15, 28, 30, 31].
The most marked differences between diffuse-CL and
disseminated-CL are the presence of multiple non-
ulcerative nodular lesions, a poor T cell response to
Leishmania antigen, and a high number of phagocy-
tosed Leishmania parasites within macrophages found
in the former but not in the latter [6]. Characteristics of
the present diffuse-CL patient corresponded to the pre-
viously reported cases, showing non-ulcerative lesions,
negative skin test, and innumerable amastigotes in
phagocytes. Silveira et al. proposed two pathogenicity
extremes, the hypersensitivity pole by MCL and the
Table 1 A bibliographic summary of the differences between diffuse-CL and disseminated-CL cutaneous leishmaniasis in the
New and Old Worlds
Characteristics DCL DSL
Main agents
In the New World L. (L.) amazonensis L. (V.) braziliensis group
L. (L.) mexicana L. (L.) mexicana group
In the Old World L. (L.) aethiopica No specific case reports other
than HIV co-infection
L. (L.) major
No. of parasites in lesions/smears Massive/abundant in smear
(uncontrolled parasite growth)
Scanty/rare in smear
Leishmanin skin test Negative/poor (specifically anergic
to Leishmania antigen;
lack of cell-mediated immunity)
Strongly positive
Reaction to TB, PPD, and other antigens Yes Yes
Antibody response Elevated, rK39+a Elevated, rK39+a
Ulceration of lesions Never (non-necrotizing) Frequent (necrotizing)
Coalescence to form plaques Frequent Rare
Type of lesions Nodules, papules, plaques, macules, erythema Papules, nodules, ulcers
(mixture of small lesions)
Typical lesion Lepromatous Acneiform
Response to drug/therapy Resistant/poor, relapse frequently Good/poor
Infection/clinical course Chronic, persist 20 years or more, for a life long Not chronic
Analogous to lepromatous leprosy Yes No
Affected ages and sex All ages and sexes Young adults, maleb
No. of lesions Often innumerable, plaques on body surface 0–300b, 308c, 425d, 745e
Mucosal involvement No Frequentb
Disease entity Rare, less than 0.1 % of total CL in Venezuelaf Less than 2 % of CLb
aHashiguchi et al., unpublished data
bTuretz et al. [7]
cLazo and Hashiguchi [15]
dCouppie et al. [30]
eSousa et al. [31]
fConvit et al. [28]
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they recommended the use of the term “borderline/
disseminated-CL (BDCL)” for the disseminated form,
caused by parasites of the subgenera Leishmania and
Viannia, which might be regarded as intermediate
between localized CL and the extreme pathogenicity
poles MCL and ADCL [32]. Disseminated-CL is distrib-
uted widely in the New World and is characterized by
cutaneous lesions, which may be accompanied by mucosal
involvement and demonstrate a tendency toward
chronicity and relapse as well as resistance to standard
treatment regimens; parasites of the subgenus Viannia, L.
(V.) braziliensis and L. (V.) guyanensis/panamensis, have
been identified as the major etiological agent of this subset
of infections [6, 7, 30, 33]. The disseminated-CL is also
characterized by the presentation of a large number of
acneiform and papular skin lesions, sometimes more
than 700, at different anatomical regions such as the
body surface, face, limbs, and trunks [7]. Most of thedisseminated-CL lesions appear simultaneously with or sec-
ondary to one or several ulcerated lesions of localized CL.
In an area of northeastern Brazil where L. (V.) braziliensis
is endemic, patients with disseminated-CL presented
10–300 lesions that were a mixture of acneiform,
papular, nodular, and ulcerated types; 12 (29 %) of 42
patients had mucosal involvement; and the patients with
disseminated-CL had lower levels of interferon-γ and
tumor necrosis factor-α production, compared with
localized-CL patients [7]. An association between
disseminated-CL and L. (V.) braziliensis strain poly-
morphisms was suggested that molecular genotyping
may provide markers to identify the strains likely to cause
an emerging, hard-to-treat form of disseminated-CL [34].
In the Old World, several cases are literary reported
as “disseminated-CL,” but those are co-infection with
HIV, caused by L. (L.) major or other unknown species of
the subgenus Leishmania [35]. The cases are different
from those found in the New World.
Hashiguchi et al. Tropical Medicine and Health  (2016) 44:2 Page 8 of 9In the current study, rK39 rapid kit test revealed
positive bands both for the sera of diffuse-CL and
disseminated-CL patients. The kit test using L. (L.)
chagasi antigen is prepared for the qualitative detection
of antibodies to L. (L.) donovani complex in human
serum (InBios International, Instructions). However,
we applied the test to our cases, expecting the cross-
reactions between the Leishmania species, and ob-
served strong positive bands in the cases. Furthermore,
in our preliminary study, positive reaction of rK39 kit
test against the serum of a MCL patient was also ob-
served, but no positive reaction was found in the sera of
localized-CL and mucosal (ML) patients; both are acute
and/or relatively mild cases of CL (Hashiguchi et al.,
unpublished data). Cross-reactions of the rK39 kit test are
reported at some extent. For example, positivity in at least
one test employing recombinant (rK39) antigen was
observed in 24 (45 %) patients with CL from Venezuela
and Brazil and 47 (82.4 %) with Plasmodium vivax or P.
falciparum from Brazil [36]. On the contrary, using the
rK39 kit test, 100 % of the samples from 272 subjects with
confirmed CL was negative, confirming the absolute
absence of a serological cross-reaction [37]. Based on
these results, Molinet et al. proposed the recommendation
that the lack of a cross-reaction in CL patients infected by
parasites of the same genus highlights the specificity of
the rK39 antigen for the diagnosis of VL in areas with the
sympatric circulation of L. (V.) braziliensis and L. (L.)
infantum in Brazil [37]. Furthermore, Maia et al.
mentioned that the rK39 proteins used either in a strip
test or in an ELISA and the DAT are the best choices for
implementation of rapid, easy, and efficient test for
serodiagnosis of VL, performing a systematic review and
meta-analysis of the studies published [38].Conclusions
In conclusion, the terms, diffuse-CL and disseminated-
CL, should be used more correctly, based on the clinical,
parasitological, and immunological features of the two
forms. Furthermore, diffuse-CL is highly resistant to the
drugs, and no specific and efficient medication is available
for this disease form in the world. Therefore, the diffuse-CL
should be diagnosed precisely at the early phase of
the disease, differentiating from disseminated-CL which is
sensitive against the available drugs.
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